Literature DB >> 11726219

Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes.

K A Berlyn1, B Schultes, B Leveugle, A A Noujaim, R B Alexander, D L Mann.   

Abstract

Dendritic cells (DC) acquire antigens through a number of cell surface structures including receptors for the Fc portion of immunoglobulins and mannose. Little is known about the effects of antigen uptake via these receptors on antigen processing and presentation. We compared the capacity of DC to generate CD4(+) and CD8(+) T cell responses after exposure to prostate-specific antigen (PSA) alone, PSA targeted to the mannose receptor (mannosylated PSA (PSA-m)), or PSA targeted to Fc receptors by combining PSA with an anti-PSA antibody (AR47.47). Autologous CD3(+) T cells were added to monocyte-derived immature DC that had been cultured with GM-CSF/IL-4 for 4 days, exposed to antigen, and matured with CD40L or TNFalpha/IFN-alpha. After several rounds of stimulation, T cell responses were assessed by intracellular IFN-gamma production using flow cytometry. Both CD4(+) and CD8(+) T cell responses were observed after stimulation with DC exposed to the PSA/anti-PSA complexes, whereas CD4(+) predominated over CD8(+) T cell responses after stimulation with PSA-armed DC or PSA-m. These CD8(+) T cells responded when rechallenged with DC pulsed with HLA allele-restricted PSA peptides. These results indicate that PSA and PSA-m are processed primarily through pathways that favor HLA Class II presentation, while the PSA/anti-PSA immune complexes are processed through both Class I and Class II pathways in monocyte-derived DC. These findings have potential applications in designing more effective cancer vaccines for prostate cancer. (c)2001 Elsevier Science.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11726219     DOI: 10.1006/clim.2001.5115

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  17 in total

1.  Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaques.

Authors:  Francois Villinger; Ann E Mayne; Pavel Bostik; Kazuyasu Mori; Peter E Jensen; Rafi Ahmed; Aftab A Ansari
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation.

Authors:  Mitsutoshi Matsuo; Yasuhiro Nagata; Eiichi Sato; Djordje Atanackovic; Danila Valmori; Yao-Tseng Chen; Gerd Ritter; Ira Mellman; Lloyd J Old; Sacha Gnjatic
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-21       Impact factor: 11.205

Review 3.  Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens.

Authors:  L Jeannine Brady
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

Review 4.  The common sense of the self-nonself discrimination.

Authors:  Melvin Cohn
Journal:  Springer Semin Immunopathol       Date:  2005-02-15

Review 5.  Does the signal for the activation of T cells originate from the antigen-presenting cell or the effector T-helper?

Authors:  Melvin Cohn
Journal:  Cell Immunol       Date:  2006-09-11       Impact factor: 4.868

6.  Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.

Authors:  David J DiLillo; Jeffrey V Ravetch
Journal:  Cell       Date:  2015-05-11       Impact factor: 41.582

Review 7.  IgE immunotherapy against cancer.

Authors:  Lai Sum Leoh; Tracy R Daniels-Wells; Manuel L Penichet
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

8.  Humoral response to a viral glycan correlates with survival on PROSTVAC-VF.

Authors:  Christopher T Campbell; James L Gulley; Oyindasola Oyelaran; James W Hodge; Jeffrey Schlom; Jeffrey C Gildersleeve
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-14       Impact factor: 11.205

Review 9.  IgE immunotherapy: a novel concept with promise for the treatment of cancer.

Authors:  Debra H Josephs; James F Spicer; Panagiotis Karagiannis; Hannah J Gould; Sophia N Karagiannis
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

10.  A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy.

Authors:  Tracy R Daniels-Wells; Gustavo Helguera; Richard K Leuchter; Rafaela Quintero; Maggie Kozman; José A Rodríguez; Elizabeth Ortiz-Sánchez; Otoniel Martínez-Maza; Birgit C Schultes; Christopher F Nicodemus; Manuel L Penichet
Journal:  BMC Cancer       Date:  2013-04-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.